Atossa Therapeutics brings experts together to examine endocrine therapy backbone potential

Atossa Therapeutics brings experts together to examine endocrine therapy backbone potential
Atossa KOL event on cancer therapy

Atossa Therapeutics, Inc. will host a virtual Key Opinion Leader (KOL) event on May 19 to focus on the development of (Z)-endoxifen as a potential backbone endocrine therapy for multiple estrogen receptor-positive breast cancer settings.

The event will feature Dr. Laura Esserman, founder and principal investigator, who brings extensive expertise in breast cancer research and innovation. This initiative underscores Atossa Therapeutics efforts to accelerate research and collaboration in potential next-generation endocrine therapies. Investors and medical professionals will closely watch the outcomes of this gathering.

Atossa Therapeutics recently took part in LSINW2026 in Seattle, meeting with industry leaders to advance cell therapy innovation momentum (article). The company also received FDA Rare Pediatric Disease designation for Z-endoxifen in the treatment of McCune-Albright Syndrome (article). These developments reflect ongoing progress in Atossa’s therapeutic pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.